Business Wire

CA-ENERGOUS

26.2.2020 22:04:06 CET | Business Wire | Press release

Share
Energous Secures Industry-first Regulatory Approval for its Revolutionary WattUp Wireless Charging Technology in Japan

Today Energous Corporation (Nasdaq: WATT), the developer of WattUp®, a revolutionary wireless charging 2.0 technology, announced that it has received regulatory approval for its WattUp Near Field wireless charging technology in Japan.

“Having secured regulatory approval for our WattUp wireless charging technology in Japan is a major regulatory milestone for Energous,” said Stephen R. Rizzone, president and CEO of Energous Corporation. “This opens the door to sell WattUp-enabled products in a major Asia Pacific market.”

Energous’ WattUp wireless charging technology underwent testing by independent, accredited test labs and was determined to be compliant with all regulatory requirements in Japan.

“WattUp approval in Japan is a big step forward for Energous and our customers, while increasing momentum to achieve global market access,” said Dan Lawless, vice president of regulatory affairs at Energous Corporation. “We are establishing a regulatory framework for the large-scale deployment of wireless charging 2.0 through our substantial engagements in major international spectrum and standards organizations, combined with our direct work with governments around the world.”

“Currently wireless charging technologies – specifically non coil-based charging solutions – have not yet penetrated the Japan market, largely because Japan has historically proven to have a more rigid regulatory approval process. Energous Corporation is paving the way for the industry in the Japan market with the industry-first approval of its WattUp wireless charging technology. With this breakthrough, Energous continues to show progress in advancing its WattUp technology to meet the needs of partner and customer companies,” said Dinesh Kithany, lead industry analyst, wireless power and power supply at Omdia.

Some of the benefits of Energous’ WattUp technology for manufacturers include:

  • A small footprint allowing WattUp to be integrated into products of various form factors, including small devices with curved edges or without flat surfaces
  • Orientation freedom and 90-degree angle support
  • Foreign object detection eliminating thermal issues with metal and other materials
  • Interoperability with all WattUp-enabled products, even those from different manufacturers

To-date, Energous has secured regulatory approval for its WattUp wireless charging technology in the following countries:

Afghanistan

Bermuda

Curacao

Germany

Kosovo

Netherlands

Suriname

Albania

Bolivia

Cyprus

Ghana

Latvia

New Zealand

Sweden

Andorra

Bosnia and Herzegovina

Czech Republic

Greece

Liechtenstein

Nicaragua

Switzerland

Angola

Botswana

Denmark

Grenada

Lithuania

Norway

Taiwan

Antigua and Barbuda

Brazil

Djibouti

Guatemala

Luxembourg

Panama

Tajikistan

Argentina

Brunei

Dominican Republic

Guyana

Macedonia

Peru

Tanzania

Armenia

Bulgaria

Dominica

Honduras

Malawi

Philippines

Thailand

Aruba

Burkina Faso

Ecuador

Hungary

Maldives

Poland

Trinidad and Tobago

Australia

Cambodia

Egypt

Iceland

Malta

Portugal

Turkey

Austria

Canada

El Salvador

India

Mexico

Romania

United Arab Emirates

Azerbaijan

Cayman Island

Eritrea

Indonesia

Monaco

Serbia

Uganda

Bahamas

Central African Republic

Estonia

Ireland

Mongolia

Slovenia

The United Kingdom

Barbados

Chile

Ethiopia

Italy

Montenegro

Solomon Island

The United States

Belarus

Colombia

Finland

Jamaica

Mozambique

Slovakia

Uruguay

Belgium

Costa Rica

France

Japan

Myanmar (formerly Burma)

South Africa

Uzbekistan

Belize

Croatia

Georgia

Jordan

Nepal

Spain

Venezuela

Energous anticipates it will receive regulatory approval in additional markets later this year.

To learn more about Energous, please visit Energous.com or follow the company on Twitter , Facebook and LinkedIn .

About Energous Corporation

Energous Corporation (Nasdaq: WATT) is leading the next generation of wireless charging – wireless charging 2.0 – with its award-winning WattUp® technology, which supports fast, efficient contact-based charging, as well as charging at a distance. WattUp is a scalable, RF-based wireless charging technology that offers substantial improvements in contact-based charging efficiency, foreign object detection, orientation freedom and thermal performance compared to older, coil-based charging technologies. The technology can be designed into many different sized electronic devices for the home and office, as well as the medical, industrial, retail and automotive industries, and it ensures interoperability across products. Energous develops silicon-based wireless power transfer (WPT) technologies and customizable reference designs. These include innovative silicon chips, antennas and software, for a large variety of applications, such as smartphones, fitness trackers, hearables, medical sensors and more. Energous received the world’s first FCC Part 18 certification for at-a-distance wireless charging, and the company has 220 awarded patents for its WattUp wireless charging technology to-date. For more information, please visit Energous.com .

Safe Harbor Statement

This press release contains forward-looking statements that describe our future plans and expectations. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of our forward-looking statements in this release include our statements about technology developments, partner product development and wireless charging innovation. Our forward-looking statements speak only as of this date; they are based on current expectations and we undertake no duty to update them. Factors that could cause actual results to differ from what we expect include: uncertain timing of necessary regulatory approvals; timing of customer product development and market success of customer products; our dependence on distribution partners; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, in evaluating our forward-looking statements.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye